

Clinical Trial Protocol

Iranian Registry of Clinical Trials

23 Jun 2026

Comparison of the effect of intralesional injection of triamcinolone acetonide with the simultaneous combination of triamcinolone acetonide and 5-fluoracil in the treatment of hypertrophic scars

Protocol summary

Study aim

Comparison of the effect of intralesional injection of triamcinolone acetonide with the simultaneous combination of triamcinolone acetonide and 5-fluoracil in the treatment of hypertrophic scars

Design

This is a randomized, and non-blinded clinical trial with a parallel design. In this randomized study, 40 eligible patients will be included in the study. A table of random numbers is used for randomization, and the participants are assigned to two intervention groups.

Settings and conduct

This study, which will be conducted in the Haj Dayi Clinic of Kermanshah, is nonblinded. The two studied groups will be matched in terms of age, gender, and duration of the lesion.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Informed consent Exclusion criteria: Patients under treatment for the last 6 months; Pregnant patients or those planning to become pregnant; Lactating women; Chronic kidney disease patients or those with any abnormal changes in CBC or liver function tests

Intervention groups

In the first intervention group, 20 mg of triamcinolone acetonide (manufactured by Alborz Company) will be used inside the lesion once every four weeks for 6 treatment sessions (that is, injection of 50% of triamcinolone acetonide (40 mg). In the second intervention group, 50% triamcinolone acetonide injection (40 mg) and 50% 5-Fluoracil (manufactured by Alborz company) (50 mg) will be used. Finally, the combination of 20 mg of triamcinolone acetonide with 25 mg of 5-Fluoracil is prepared for injection and is injected to patients every 4 weeks.

Main outcome variables

the intensity of itching of the lesion; the intensity of

redness of the lesion; Length, width, and height of the lesion

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20130812014333N189**

Registration date: **2022-10-25, 1401/08/03**

Registration timing: **prospective**

Last update: **2022-10-25, 1401/08/03**

Update count: **0**

Registration date

2022-10-25, 1401/08/03

Registrant information

Name

Feizollah Foroughi

Name of organization / entity

kermanshah University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 83 1821 4653

Email address

froughi@kums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-11-16, 1401/08/25

Expected recruitment end date

2023-01-05, 1401/10/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the effect of intralesional injection of triamcinolone acetonide with the simultaneous combination of triamcinolone acetonide and 5-fluoracil in the treatment of hypertrophic scars

Public title

Comparison of the effect of intralesional injection of triamcinolone acetonide with the simultaneous combination of triamcinolone acetonide and 5-fluoracil

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Informed consent

Exclusion criteria:

Patients under treatment for the last 6 months Pregnant patients or those planning to become pregnant Lactating women Chronic kidney disease patients or those with any abnormal changes in CBC or liver function tests

Age

No age limit

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **40**

Randomization (investigator's opinion)

Randomized

Randomization description

Using the random number table, patients are divided into two groups of 20. Each patient is assigned a 4-digit code based on the random number table; based on the right number of patients' codes, the patients are divided into two groups. Patients whose last digit is 2, 4, 6, and 8 will be assigned to the intervention group, and patients whose last digit is 1,3,5, and 7 will be assigned to the control group.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Kermanshah University of Medical Sciences

Street address

Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences, Building No.2, Shahid Beheshti Boulevard

City

Kermanshah

Province

Kermanshah

Postal code

6715847141

Approval date

2022-06-26, 1401/04/05

Ethics committee reference number

IR.KUMS.MED.REC.1401.068

Health conditions studied**1****Description of health condition studied**

Hypertrophic scar

ICD-10 code**ICD-10 code description****Primary outcomes****1****Description**

Intensity of itching of the lesion

Timepoint

First, fourth and sixth week

Method of measurement

Based on examination and questioning of the patient

2**Description**

Redness intensity of the lesion

Timepoint

First, fourth and sixth week

Method of measurement

Based on examination

3**Description**

Length, width and height of the lesion

Timepoint

First, fourth and sixth week

Method of measurement

Based on examination

Secondary outcomes

empty

Intervention groups

1

Description

In the first intervention group, 20 mg of triamcinolone acetonide (manufactured by Alborz Company) will be used inside the lesion once every four weeks for 6 treatment sessions (that is, injection of 50% of triamcinolone acetonide (40 mg).

Category

Treatment - Drugs

2

Description

In the second intervention group, 50% triamcinolone acetonide injection (40 mg) and 50% 5-Fluoracil (manufactured by Alborz company) (50 mg) will be used. Finally, the combination of 20 mg of triamcinolone acetonide in 25 mg of 5-Fluoracil is prepared for injection and is injected to patients every 4 weeks.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Haji Dayi skin clinic

Full name of responsible person

Abdolhamid Ebrahimi

Street address

Golestan Crossroads

City

Kermanshah

Province

Kermanshah

Postal code

6714647147

Phone

+98 83 3845 3486

Email

pamiebi1377@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Dr. Cyrus Jalili

Street address

Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences, Building No.2, Shahid Beheshti Boulevard

City

Kermanshah

Province

Kermanshah

Postal code

6715847141

Phone

+98 83 3836 0014

Email

cjalili@kums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Kermanshah University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Abdolhamid Ebrahimi

Position

Resident of Skin

Latest degree

Medical doctor

Other areas of specialty/work

Skin

Street address

School of Medicine, parastar boulevard

City

Kermanshah

Province

Kermanshah

Postal code

6715847141

Phone

+98 83 3427 4618

Email

pamiebi1377@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Dr. Hossein Kavosi

Position

Member of the academic staff of Kermanshah
University of Medical Sciences

Latest degree

Specialist

Other areas of specialty/work

Skin

Street address

School of Medicine, parastar boulevard

City

Kermanshah

Province

Kermanshah

Postal code

6715847141

Phone

+98 83 3427 4618

Email

hkawosi@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Abdolhamid Ebrahimi

Position

Resident of Skin

Latest degree

Medical doctor

Other areas of specialty/work

Skin

Street address

School of Medicine, parastar boulevard

City

Kermanshah

Province

Kermanshah

Postal code

6715847141

Phone

+98 83 3427 4618

Email

pamiebi1377@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

There is no further information

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available